To know more about 57357 Covid-19 Clinic
Click here

A 57357 research studying neuroblastoma patients with opsolclonus myoclonus ataxia syndrome

    Published in: Journal of pediatric hematology oncology Impact factor: 1.8 Opsoclonous myoclonous ataxia syndrome (OMAS) (is the syndrome where antibodies cross brain barrier and react with cerebellum causing behavioral and motor disorder) It is a rare primarily immune-mediated disease in children. The study aims to find out the patterns and outcome of OMAS associated with … Continued

Published in: Journal of pediatric hematology oncology

Impact factor: 1.8

Opsoclonous myoclonous ataxia syndrome (OMAS) (is the syndrome where antibodies cross brain barrier and react with cerebellum causing behavioral and motor disorder) It is a rare primarily immune-mediated disease in children. The study aims to find out the patterns and outcome of OMAS associated with neuroblastoma (NBL) cancer among Children’s Cancer Hospital—Egypt patients. Data was reviewed for 15 eligible patients enrolled between 2007 and 2016.

Median time till improvement of manifestations was 5 months. The median time to progression was 28 months measured from OMAS diagnosis. All patients remained alive with NBL 5-year overall survival of 100% and event-free survival of 85.7%. However, 73% of the patients showed late complications ranging from ocular to cognitive, behavioral and motor disorders; rarely seizures and hemolytic anemia.